FindTrial
Sign In

It is the study for analysis of patients of carcinoma esophagus and gastroesophageal junction who have received chemotherapy before.

Retrospective analysis of patients who have received docetaxel, platinum, and 5-fluorouracil as induction chemotherapy for ca esophagus and gastroesophageal junction.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2014/08/004839
Enrollment
31
Registered
2014-08-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients of ca esophagus and gastroesophageal junction who have received docetaxel, platinum and 5-Fluorouracil as induction therapy

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: We will include patients who have received DCF induction chemotherapy for potentially resectable esophageal and GE junction carcinoma, from January 2010 to May 2014, whose data has been prospectively entered in a database that has been maintained in the medical oncology department at Tata Memorial Hospital.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
To assess the pathologic complete remission rate of DCF induction chemotherapy in locally advanced resectable or borderline resectable CA of esophagus or GE junction. Timepoint: Post Surgery—

Secondary

MeasureTime frame
1. Toxicity 2. Response rate 3. Resection rate 4. R0 resection rate 5. Overall survival 6. Progression-free survival 7. Evaluate factors that affect survival. Timepoint: 1. Every 3 weeks on chemotherapy for Toxicity 2. R0 resection rate: at the time of Surgery 3. For progression free survival & Overall survival: Every 3 months for 3 years. 4. Response Rate:Following chemotherapy 1 to 2 weeks after last cycle of induction chemotherapy.—

Countries

India

Contacts

Public ContactDr Vanita Noronha

TATA MEMORIAL HOSPITAL

vanita.noronha@gmail.com9769328047

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026